<p>根據 Vanguard Group Inc.最近向證券交易委員會的披露，該公司在 Tango Therapeutics, Inc.（NASDAQ:TNGX - 免費報告）第四季度的持股增長了 33.6%。該基金在此期間購買了額外的 1,698,974 股後，持有該公司 6,750,977 股股票。Vanguard Group Inc.在最近一個季度末持有 Tango Therapeutics 約 5.01% 的股份，價值 59,814,000 美元。</p>
<p>獲取 <strong>Tango Therapeutics</strong> 的提醒：</p>
<p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度將其在 Tango Therapeutics 的持股增加了 148,800.0%。Zurcher Kantonalbank Zurich Cantonalbank 現在持有 4,467 股該公司的股票，價值 40,000 美元，此前在上個季度購買了額外的 4,464 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Tango Therapeutics 的持股增加了 52.2%。Mirae Asset Global Investments Co. Ltd.現在持有 6,544 股該公司的股票，價值 58,000 美元，此前在上個季度購買了額外的 2,243 股。Legal &amp; General Group Plc 在第二季度將其在 Tango Therapeutics 的持股增加了 30.7%。Legal &amp; General Group Plc 現在持有 6,985 股該公司的股票，價值 36,000 美元，此前在上個季度購買了額外的 1,640 股。Russell Investments Group Ltd.在第三季度將其在 Tango Therapeutics 的持股增加了 461.3%。Russell Investments Group Ltd.現在持有 7,729 股該公司的股票，價值 65,000 美元，此前在上個季度購買了額外的 6,352 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Tango Therapeutics 的持股增加了 44.3%。Tower Research Capital LLC TRC 現在持有 9,473 股該公司的股票，價值 49,000 美元，此前在上個季度購買了額外的 2,907 股。目前 78.99% 的股票由機構投資者和對沖基金持有。</p>
<h2>Tango Therapeutics 的內部活動</h2>
<p>在其他 Tango Therapeutics 的新聞中，內部人士 Adam Crystal 於 2 月 25 日星期三出售了 54,345 股該公司的股票。股票以平均價格 12.77 美元出售，總價值為 693,985.65 美元。交易後，該內部人士直接持有 132,873 股公司股票，價值 1,696,788.21 美元。此次交易使其持股減少了 29.03%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。內部人士在過去 90 天內已出售 179,056 股公司股票，價值 3,346,181 美元。6.50% 的股票由內部人士持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些分析師最近對該股票發佈了報告。HC Wainwright 將 Tango Therapeutics 的股票目標價從 13.00 美元上調至 27.00 美元，並在 3 月 6 日的報告中給予該公司 “買入” 評級。Weiss Ratings 在週一的報告中將 Tango Therapeutics 的股票評級從 “賣出（e+）” 上調至 “賣出（d-）”。Wall Street Zen 在 3 月 21 日的報告中將 Tango Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Leerink Partners 在週四的報告中將 Tango Therapeutics 的股票目標價從 28.00 美元上調至 55.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Canaccord Genuity Group 在 4 月 2 日的報告中開始覆蓋 Tango Therapeutics 的股票。他們設定了 “買入” 評級和 30.00 美元的目標價。十位股票研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 31.36 美元。</p>
<p><strong>查看我們關於 Tango Therapeutics 的最新股票報告</strong></p>
<h2>Tango Therapeutics 股價下跌 2.5%</h2>
<p>TNGX 的股票在週五開盤價為 24.87 美元。該公司的市值為 35.9 億美元，市盈率為-29.96，貝塔值為 1.22。Tango Therapeutics, Inc.的 1 年最低價為 1.25 美元，1 年最高價為 28.41 美元。該公司的 50 日簡單移動平均線為 21.41 美元，200 日簡單移動平均線為 14.20 美元。</p>
<p>Tango Therapeutics（NASDAQ:TNGX - 獲取免費報告）最後一次發佈財報是在 5 月 13 日星期三。該公司報告季度每股收益為-0.32 美元，符合分析師的共識預期（-0.32 美元）。Tango Therapeutics 的淨利潤率為-151.15%，股本回報率為-50.17%。作為一個整體，研究分析師預測 Tango Therapeutics, Inc.在當前年度將發佈-1.35 的每股收益。</p>
<h2>關於 Tango Therapeutics</h2>
<p>（免費報告）</p>
<p>Tango Therapeutics 是一家臨牀階段的生物技術公司，致力於開發利用癌細胞遺傳脆弱性的精準醫學。該公司利用專有的合成致死平台，識別並針對 DNA 損傷反應及相關通路中的腫瘤特異性依賴性。通過關注腫瘤細胞的附帶敏感性，Tango 旨在為具有遺傳改變的患者提供差異化的小分子療法，這些改變使其更容易受到靶向抑制。</p>
<p>該公司的主要研發管線包括多個早期階段的項目，包括旨在選擇性地禁用腫瘤細胞中的 DNA 修復蛋白，同時保護正常組織的抑制劑。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tango Therapeutics</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度財報後的表現比較</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
<p><strong>想知道其他對 TNGX 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Tango Therapeutics, Inc. (NASDAQ:TNGX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Tango Therapeutics 嗎？</h2>
<p>在考慮 Tango Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tango Therapeutics 並不在名單上。</p>
<p>雖然 Tango Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TNGX

<p>先鋒集團在第四季度將其在 Tango Therapeutics, Inc.的持股增加了 33.6%，持有 6,750,977 股，價值 5981 萬美元。其他機構投資者也提高了他們的持股比例。內部人士 Adam Crystal 出售了 54,345 股，減少了 29.03% 的持股。分析師的評級意見不一，普遍目標價為 31.36 美元。Tango 的股票開盤價為 24.87 美元，下跌 2.5%。該公司報告每股收益為（0.32 美元），與預期一致</p>

<p>Vanguard Group Inc. grew its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 33.6% during the fourth quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 6,750,977 shares of the company's stock after purchasing an additional 1,698,974 shares during the period. Vanguard Group Inc. owned about 5.01% of Tango Therapeutics worth $59,814,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據 Vanguard Group Inc.最近向證券交易委員會的披露，該公司在 Tango Therapeutics, Inc.（NASDAQ:TNGX - 免費報告）第四季度的持股增長了 33.6%。該基金在此期間購買了額外的 1,698,974 股後，持有該公司 6,750,977 股股票。Vanguard Group Inc.在最近一個季度末持有 Tango Therapeutics 約 5.01% 的股份，價值 59,814,000 美元。</p>
</div><p>Get <strong>Tango Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tango Therapeutics</strong> 的提醒：</p>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock valued at $40,000 after purchasing an additional 4,464 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company's stock valued at $58,000 after purchasing an additional 2,243 shares during the last quarter. Legal &amp; General Group Plc raised its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal &amp; General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Tango Therapeutics by 461.3% in the third quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company's stock valued at $65,000 after purchasing an additional 6,352 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company's stock valued at $49,000 after purchasing an additional 2,907 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也對該公司的持倉進行了調整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度將其在 Tango Therapeutics 的持股增加了 148,800.0%。Zurcher Kantonalbank Zurich Cantonalbank 現在持有 4,467 股該公司的股票，價值 40,000 美元，此前在上個季度購買了額外的 4,464 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Tango Therapeutics 的持股增加了 52.2%。Mirae Asset Global Investments Co. Ltd.現在持有 6,544 股該公司的股票，價值 58,000 美元，此前在上個季度購買了額外的 2,243 股。Legal &amp; General Group Plc 在第二季度將其在 Tango Therapeutics 的持股增加了 30.7%。Legal &amp; General Group Plc 現在持有 6,985 股該公司的股票，價值 36,000 美元，此前在上個季度購買了額外的 1,640 股。Russell Investments Group Ltd.在第三季度將其在 Tango Therapeutics 的持股增加了 461.3%。Russell Investments Group Ltd.現在持有 7,729 股該公司的股票，價值 65,000 美元，此前在上個季度購買了額外的 6,352 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Tango Therapeutics 的持股增加了 44.3%。Tower Research Capital LLC TRC 現在持有 9,473 股該公司的股票，價值 49,000 美元，此前在上個季度購買了額外的 2,907 股。目前 78.99% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Activity at Tango Therapeutics</h2>
<div class="lb-trans"><h2>Tango Therapeutics 的內部活動</h2>
</div><p>In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total value of $693,985.65. Following the transaction, the insider directly owned 132,873 shares in the company, valued at $1,696,788.21. The trade was a 29.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders have sold 179,056 shares of company stock valued at $3,346,181 in the last 90 days. 6.50% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Tango Therapeutics 的新聞中，內部人士 Adam Crystal 於 2 月 25 日星期三出售了 54,345 股該公司的股票。股票以平均價格 12.77 美元出售，總價值為 693,985.65 美元。交易後，該內部人士直接持有 132,873 股公司股票，價值 1,696,788.21 美元。此次交易使其持股減少了 29.03%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。內部人士在過去 90 天內已出售 179,056 股公司股票，價值 3,346,181 美元。6.50% 的股票由內部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Tango Therapeutics from $13.00 to $27.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 6th. Weiss Ratings upgraded shares of Tango Therapeutics from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a report on Monday. Wall Street Zen downgraded shares of Tango Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 21st. Leerink Partners boosted their target price on shares of Tango Therapeutics from $28.00 to $55.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Finally, Canaccord Genuity Group started coverage on shares of Tango Therapeutics in a report on Thursday, April 2nd. They set a &#34;buy&#34; rating and a $30.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $31.36.</p>
<div class="lb-trans"><p>一些分析師最近對該股票發佈了報告。HC Wainwright 將 Tango Therapeutics 的股票目標價從 13.00 美元上調至 27.00 美元，並在 3 月 6 日的報告中給予該公司 “買入” 評級。Weiss Ratings 在週一的報告中將 Tango Therapeutics 的股票評級從 “賣出（e+）” 上調至 “賣出（d-）”。Wall Street Zen 在 3 月 21 日的報告中將 Tango Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Leerink Partners 在週四的報告中將 Tango Therapeutics 的股票目標價從 28.00 美元上調至 55.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Canaccord Genuity Group 在 4 月 2 日的報告中開始覆蓋 Tango Therapeutics 的股票。他們設定了 “買入” 評級和 30.00 美元的目標價。十位股票研究分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 31.36 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Tango Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Tango Therapeutics 的最新股票報告</strong></p>
</div><h2>Tango Therapeutics Trading Down 2.5%</h2>
<div class="lb-trans"><h2>Tango Therapeutics 股價下跌 2.5%</h2>
</div><p>Shares of TNGX opened at $24.87 on Friday. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -29.96 and a beta of 1.22. Tango Therapeutics, Inc. has a 1-year low of $1.25 and a 1-year high of $28.41. The company's fifty day simple moving average is $21.41 and its 200 day simple moving average is $14.20.</p>
<div class="lb-trans"><p>TNGX 的股票在週五開盤價為 24.87 美元。該公司的市值為 35.9 億美元，市盈率為-29.96，貝塔值為 1.22。Tango Therapeutics, Inc.的 1 年最低價為 1.25 美元，1 年最高價為 28.41 美元。該公司的 50 日簡單移動平均線為 21.41 美元，200 日簡單移動平均線為 14.20 美元。</p>
</div><p>Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.17%. As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tango Therapeutics（NASDAQ:TNGX - 獲取免費報告）最後一次發佈財報是在 5 月 13 日星期三。該公司報告季度每股收益為-0.32 美元，符合分析師的共識預期（-0.32 美元）。Tango Therapeutics 的淨利潤率為-151.15%，股本回報率為-50.17%。作為一個整體，研究分析師預測 Tango Therapeutics, Inc.在當前年度將發佈-1.35 的每股收益。</p>
</div><h2>About Tango Therapeutics</h2>
<div class="lb-trans"><h2>關於 Tango Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.</p>
<div class="lb-trans"><p>Tango Therapeutics 是一家臨牀階段的生物技術公司，致力於開發利用癌細胞遺傳脆弱性的精準醫學。該公司利用專有的合成致死平台，識別並針對 DNA 損傷反應及相關通路中的腫瘤特異性依賴性。通過關注腫瘤細胞的附帶敏感性，Tango 旨在為具有遺傳改變的患者提供差異化的小分子療法，這些改變使其更容易受到靶向抑制。</p>
</div><p>The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.</p>
<div class="lb-trans"><p>該公司的主要研發管線包括多個早期階段的項目，包括旨在選擇性地禁用腫瘤細胞中的 DNA 修復蛋白，同時保護正常組織的抑制劑。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Tango Therapeutics</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tango Therapeutics</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度財報後的表現比較</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNGX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 TNGX 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Tango Therapeutics, Inc. (NASDAQ:TNGX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tango Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tango Therapeutics 嗎？</h2>
</div><p>Before you consider Tango Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tango Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tango Therapeutics 並不在名單上。</p>
</div><p>While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tango Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

先鋒集團公司持有 Tango Therapeutics, Inc. $TNGX 價值 5981 萬美元的股份